Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Search
Our Global Support Program
Our global support programme
World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program
World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program
Alberta’s Dr. Karen Schwartzkopf-Genswein named 2022 Metacam® 20 Bovine Welfare Award winner
Award recognizes outstanding contributions to the welfare of animals in Canada
University of Saskatchewan’s Dr. Diego Moya named 2024 Metacam® Bovine Welfare Award winner
Award recognizes outstanding contributions to advancing animal welfare in Canada
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Early Careers
Early Careers
Data Careers
Data Careers
Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner
Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner
Ontario’s Dr. Trevor DeVries named 2021 Metacam® 20 Bovine Welfare Award winner
Ontario’s Dr. Trevor DeVries named 2021 Metacam® 20 Bovine Welfare Award winner
Public-Health-Cost-from-AF
Work-life-balance
It's important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats
Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats
Our Stories
Find out more about us by reading our stories. Below are the latest press releases, news stories, and more from our family around the world.
Our Animal Health story
Our Animal Health story
GPP
GPP
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Inadvertent self-injection: The risk associated with oil-based vaccines
Inadvertent self-injection: The risk associated with oil-based vaccines
Global mobility
We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Choose the better engineered teat sealant
Choose the better engineered teat sealant
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.
Treatment options for parasite control in cattle
Treatment options for parasite control in cattle
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Accessible Customer Service Policy
Accessible Customer Service Policy